third quarter ended September 30, 2026
Filed Oct 13, 2026ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
The company disclosed preliminary third-quarter ZYNLONTA net product revenues and cash, alongside financing actions intended to extend expected cash runway into 2029 and reduce term-loan principal. The financing is contingent on the PIPE closing, and the release provided no finalized income statement, profitability, cash-flow, or period-over-period operating comparisons.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net product revenues from sales of ZYNLONTA, third quarter ended September 30, 2026other | approximately $21.0 million | – | – |
| Cash and cash equivalents, as of September 30, 2026other | $189.2M | – | – |
| Cash and cash equivalents, pro forma as of September 30, 2026other | approximately $196 million | – | – |
| PIPE gross proceedsother | approximately $86.6 million | – | – |
| Estimated net cash proceeds from the PIPEother | approximately $76.3 million | – | – |
| Outstanding term loans immediately after contemplated prepaymentother | $50M | – | – |
Expected cash runway outlook
- Noteextending the expected cash runway into 2029
What drove it
- The company entered into securities purchase agreements for a $86.6 million PIPE financing with institutional investors, including Bain Capital Life Sciences, Redmile, TCGX, and Nantahala Capital.
- The PIPE includes 12.9 million common shares at $1.42 per share and pre-funded warrants to purchase 48.1 million common shares at $1.32 per pre-funded warrant.
- The company intends to use PIPE net proceeds for continued funding of ZYNLONTA pipeline studies, including Phase 3 trials in diffuse large B-cell lymphoma and marginal zone lymphoma, balance-sheet strengthening, working capital, and general corporate purposes.
- The HCR Amendment eliminates the $150 million payment otherwise required solely upon a change of control.
- The Loan Agreement Amendment eliminates subsequent scheduled principal amortization and the minimum liquidity covenant.
- The minimum trailing four-quarter U.S. ZYNLONTA sales covenant is set at $65.0 million for the quarter ending December 31, 2026 and each quarter thereafter.
Concerns
- The PIPE is expected to close on October 22, 2026, subject to customary closing conditions.
- The effectiveness of the HCR Amendment is conditioned upon completion of the PIPE by October 31, 2026 and effectiveness of the Loan Agreement Amendment.
- The effectiveness of the Loan Agreement Amendment, including the contemplated prepayment, is conditioned upon completion of the PIPE.
- The reported ZYNLONTA net sales and cash figures are preliminary and unaudited, and actual financial results for the quarter ended September 30, 2026 have not been finalized.
- The company stated that subsequent information or events may lead to material differences between the preliminary financial results and results reported in subsequent SEC filings.
- Ongoing royalty obligations under the HCR Agreement will continue until the Royalty Cap.
- The company identified risks related to LOTIS-5 data, the ability to maintain accelerated approval, regulatory feedback, the ability to comply with indebtedness terms, and the ability to sustain or grow ZYNLONTA revenue.
What to watch
- Closing of the PIPE, which is expected on October 22, 2026.
- Completion and effectiveness of the HCR Amendment and Loan Agreement Amendment.
- The contemplated partial principal prepayment and resulting $50.0 million outstanding term-loan principal.
- The $65.0 million minimum trailing four-quarter U.S. ZYNLONTA sales covenant for the quarter ending December 31, 2026 and each quarter thereafter.
- LOTIS-7 and MZL data abstracts expected in early November and presentations in December at the 68th American Society of Hematology Annual Meeting.
- Finalized third-quarter results, which may differ materially from the preliminary ZYNLONTA net sales and cash figures.
Balance sheet and cash flow
- Cash and cash equivalents totaled $189.2 million as of September 30, 2026.
- On a proforma basis, giving effect to estimated net cash proceeds from the PIPE of approximately $76.3 million and the partial principal prepayment of $69.6 million (including fees) on the senior secured term loan, the Company would have had approximately $196 million of cash and cash equivalents as of that date.
- The Loan Agreement Amendment provides for the prepayment of $70.0 million principal amount of term loans, plus accrued and unpaid interest and related fees and premiums.
- Immediately after the contemplated prepayment, outstanding term loans will have a principal amount of $50.0 million.
- HCR has provided $300 million of funding to the Company to date.
Analysis
ADC Therapeutics reported preliminary and unaudited net product revenues from ZYNLONTA of approximately $21.0 million for the third quarter ended September 30, 2026. The release did not provide a prior-year or prior-quarter comparator, growth rate, product-volume detail, pricing information, or a finalized statement of operations. As a result, the filing establishes the preliminary revenue level but does not show whether commercial demand improved or deteriorated versus prior periods.
The central development is a coordinated capital restructuring rather than a conventional earnings release. The company announced a $86.6 million PIPE and expects approximately $76.3 million of net cash proceeds after placement agent fees and estimated offering expenses. The financing consists of 12.9 million common shares at $1.42 per share and pre-funded warrants to purchase 48.1 million common shares at $1.32 per pre-funded warrant. Management intends to apply proceeds to ZYNLONTA pipeline studies, balance-sheet strengthening, working capital, and general corporate purposes.
Liquidity was $189.2 million of cash and cash equivalents as of September 30, 2026. On the disclosed pro forma basis, incorporating the estimated PIPE proceeds and a partial loan repayment of $69.6 million including fees, cash and cash equivalents would have been approximately $196 million. The company stated that the restructuring extends expected cash runway into 2029, but this outcome depends on closing the PIPE and completing the related amendments.
The debt amendments reduce the contemplated outstanding term-loan principal to $50.0 million after a $70.0 million principal prepayment, eliminate subsequent scheduled principal amortization, and eliminate the minimum liquidity covenant. The revised loan also establishes a $65.0 million minimum trailing four-quarter U.S. ZYNLONTA sales covenant for the quarter ending December 31, 2026 and each quarter thereafter. Separately, the HCR Amendment eliminates the $150 million payment otherwise required solely upon a change of control, while ongoing royalty obligations remain in place until the Royalty Cap.
The near-term investment case disclosed here is driven by execution of the financing and clinical and regulatory milestones rather than reported earnings leverage. The company expects LOTIS-7 and MZL data abstracts in early November, with presentations in December at the 68th American Society of Hematology Annual Meeting. Investors should also focus on the finalized third-quarter financial statements because management explicitly stated that the preliminary ZYNLONTA net sales and cash figures are not comprehensive and may differ materially from subsequently reported results.
Management, verbatim
We are pleased to announce this robust set of improvements to our capital structure which reflect confidence in ZYNLONTA’s growth potential from both long-standing and new investors as well as from HCR and our lenders.
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
These efforts extend our expected cash runway and increase strategic optionality, as we approach much anticipated LOTIS-7 and MZL data abstracts in early November with presentations in December at the 68th American Society of Hematology Annual Meeting.
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
Not in the filing
stated, not guessed- Finalized total revenue for the third quarter ended September 30, 2026.
- Prior-year and prior-quarter total revenue and revenue growth comparisons.
- Gross profit and gross margin.
- Operating expenses.
- GAAP operating income or loss.
- Non-GAAP operating income or loss.
- GAAP net income or loss.
- Non-GAAP net income or loss.
- GAAP earnings or loss per share.
- Non-GAAP earnings or loss per share.
- Operating cash flow.
- Free cash flow.
- Revenue or operating performance by segment.
- Product revenue by geography or channel.
- Share repurchases, dividends, or other capital returns.
- Total debt balance before the contemplated prepayment.
- Interest expense and debt-service cash flow.
- A traditional forward revenue, gross-margin, operating-expense, or tax-rate outlook.
- Prior-period guidance for comparison.
- Finalized financial statements for the quarter ended September 30, 2026.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.